Home › Companies › ADAPTIVE BIOTECHNOLOGIES CORP. › 2023-2024

ADAPTIVE BIOTECHNOLOGIES CORP. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings. Page generated 02 October 2026.

5Reported items
205Asset managers
1,006Fund votes
2024-06-07Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ADAPTIVE BIOTECHNOLOGIES CORP. in the interactive database Compare manager voting policies

How asset managers voted at the ADAPTIVE BIOTECHNOLOGIES CORP. 2023-2024 meeting

Each item below shows how the 205 asset managers that disclosed a ADAPTIVE BIOTECHNOLOGIES CORP. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ADAPTIVE BIOTECHNOLOGIES CORP.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement;

SECTION 14A SAY-ON-PAY VOTES

Combines 9 wordings of this item as funds reported it.

84% fund support · no official result

FOR 84%AGAINST 16%

The 199 asset managers below cast 84% of the shares they voted on this item FOR (101,501,023 for, 19,264,148 against).

FOR: 101,501,023 (84.0%)AGAINST: 19,264,148 (15.9%)ABSTAIN: 22,888 (0.0%)NOT VOTED: 7,524 (0.0%)UNKNOWN: 214 (0.0%)

Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in ” at ADAPTIVE BIOTECHNOLOGIES CORP., 2023-2024
Asset manager	For	Against	Vote
VIKING GLOBAL INVESTORS LP	29,993,708	0	For
Vanguard	13,044,798	28,100	For
ARK ETF Trust	10,319,635	0	For
Rubric Capital Management LP	10,119,845	0	For
BlackRock	123,634	6,894,355	Against
Matrix Capital Management Company, LP	5,522,318	0	For
Nikko Asset Management Americas, Inc.	4,182,393	0	For
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	3,819,201	0	For
MFS	3,329,532	0	For
Fidelity	2,498,538	49,450	For
GEODE CAPITAL MANAGEMENT, LLC	2,440,002	0	For
State Street	2,282,657	0	For
Federated Hermes	0	2,222,485	Against
Aberdeen	0	2,058,894	Against
Nikko Asset Management Co., Ltd.	1,994,314	0	For
Charles Schwab	0	1,740,771	Against
PICTET ASSET MANAGEMENT SA	1,744,107	0	For
Man Group plc	0	1,510,880	Against
Putnam	0	1,178,006	Against
Aristotle Atlantic Partners, LLC	1,130,704	0	For
Dimensional	0	1,016,118	Against
BRAIDWELL LP	969,346	0	For
Aristotle Funds Series Trust	829,708	0	For
DDD Partners, LLC	0	744,985	Against
Northern Trust	665,847	78	For

Showing the 25 largest of 199 asset managers. See all 199 in the interactive database.

2. To elect two Class II director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2027 annual meeting of shareholders: Peter Neupert

DIRECTOR ELECTIONS

Combines 4 wordings of this item as funds reported it.

100% fund support · no official result

FOR 60%ABSTAIN 40%

The 58 asset managers below cast 100% of the shares they voted on this item FOR (23,845,865 for, 0 against).

FOR: 23,845,865 (60.3%)ABSTAIN: 15,683,447 (39.7%)

Largest asset managers voting on “To elect two Class II director nominees to serve on the board of directors of Adaptive Biotechnologies Corpora” at ADAPTIVE BIOTECHNOLOGIES CORP., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	12,805,116	0	For
ARK ETF Trust	10,319,635	0	For
MFS	0	3,329,532	Abstain
BlackRock	0	2,940,769	Abstain
Fidelity	0	2,437,190	Abstain
Aberdeen	0	1,029,447	Abstain
Federated Hermes	0	910,597	Abstain
Charles Schwab	0	870,224	Abstain
Aristotle Funds Series Trust	0	829,708	Abstain
Dimensional	0	704,002	Abstain
TIAA	0	549,742	Abstain
Prudential/PGIM	112,612	237,483	Abstain
Equitable	0	292,368	Abstain
Pacific Life	0	291,982	Abstain
Putnam	219,346	0	For
Goldman Sachs	0	190,752	Abstain
Dunham Funds	117,346	0	For
Lincoln Financial	2,369	107,207	Abstain
PRIMECAP Odyssey Funds	104,230	0	For
RBB FUND, INC.	101,932	0	For
PFM Multi-Manager Series Trust	0	90,980	Abstain
T. Rowe Price	0	80,946	Abstain
1290 Funds	0	71,325	Abstain
Northern Trust	0	70,987	Abstain
JPMorgan	63,211	0	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

3. To elect two Class II director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2027 annual meeting of shareholders: Michelle Griffin

DIRECTOR ELECTIONS

Combines 4 wordings of this item as funds reported it.

100% fund support · no official result

FOR 82%ABSTAIN 18%

The 58 asset managers below cast 100% of the shares they voted on this item FOR (32,315,659 for, 0 against).

FOR: 32,315,659 (81.8%)ABSTAIN: 7,213,653 (18.2%)

Largest asset managers voting on “To elect two Class II director nominees to serve on the board of directors of Adaptive Biotechnologies Corpora” at ADAPTIVE BIOTECHNOLOGIES CORP., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	12,805,116	0	For
ARK ETF Trust	10,319,635	0	For
MFS	0	3,329,532	Abstain
BlackRock	2,940,769	0	For
Fidelity	2,329,782	107,408	For
Aberdeen	0	1,029,447	Abstain
Federated Hermes	910,597	0	For
Charles Schwab	870,224	0	For
Aristotle Funds Series Trust	0	829,708	Abstain
Dimensional	0	704,002	Abstain
TIAA	549,742	0	For
Prudential/PGIM	112,612	237,483	Abstain
Equitable	177,172	115,196	For
Pacific Life	39,796	252,186	Abstain
Putnam	219,346	0	For
Goldman Sachs	190,752	0	For
Dunham Funds	117,346	0	For
Lincoln Financial	100,469	9,107	For
PRIMECAP Odyssey Funds	104,230	0	For
RBB FUND, INC.	101,932	0	For
PFM Multi-Manager Series Trust	0	90,980	Abstain
T. Rowe Price	0	80,946	Abstain
1290 Funds	0	71,325	Abstain
Northern Trust	70,987	0	For
JPMorgan	63,211	0	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

4. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024; and

AUDIT-RELATED

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 58 asset managers below cast 100% of the shares they voted on this item FOR (39,506,424 for, 0 against).

FOR: 39,506,424 (99.9%)ABSTAIN: 22,888 (0.1%)

Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the ye” at ADAPTIVE BIOTECHNOLOGIES CORP., 2023-2024
Asset manager	For	Vote
Vanguard	12,805,116	For
ARK ETF Trust	10,319,635	For
MFS	3,329,532	For
BlackRock	2,940,769	For
Fidelity	2,437,190	For
Aberdeen	1,029,447	For
Federated Hermes	910,597	For
Charles Schwab	870,224	For
Aristotle Funds Series Trust	829,708	For
Dimensional	704,002	For
TIAA	549,742	For
Prudential/PGIM	350,095	For
Equitable	292,368	For
Pacific Life	291,982	For
Putnam	219,346	For
Goldman Sachs	190,752	For
Dunham Funds	117,346	For
Lincoln Financial	109,576	For
PRIMECAP Odyssey Funds	104,230	For
RBB FUND, INC.	101,932	For
PFM Multi-Manager Series Trust	90,980	For
T. Rowe Price	80,946	For
1290 Funds	71,325	For
Northern Trust	70,987	For
JPMorgan	63,211	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

5. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

2% fund support · no official result

AGAINST 98%

The 3 asset managers below cast 2% of the shares they voted on this item FOR (21,608 for, 927,219 against).

FOR: 21,608 (2.3%)AGAINST: 927,219 (97.7%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at ADAPTIVE BIOTECHNOLOGIES CORP., 2023-2024
Asset manager	For	Against	Vote
NORDEA INVESTMENT MANAGEMENT AB	0	859,214	Against
JPMorgan	0	68,005	Against
ESSEX INVESTMENT MANAGEMENT CO LLC	21,608	0	For

Largest ADAPTIVE BIOTECHNOLOGIES CORP. shareholders voting in 2023-2024

Ranked by the number of ADAPTIVE BIOTECHNOLOGIES CORP. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 147,368,324 shares outstanding at the time of that meeting.

Top ADAPTIVE BIOTECHNOLOGIES CORP. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	VIKING GLOBAL INVESTORS LP	20.35%
2	Vanguard	8.87%
3	ARK ETF Trust	7.00%
4	Rubric Capital Management LP	6.87%
5	BlackRock	4.76%
6	Matrix Capital Management Company, LP	3.75%
7	Nikko Asset Management Americas, Inc.	2.84%
8	MASSACHUSETTS FINANCIAL SERVICES CO /MA/	2.59%
9	MFS	2.26%
10	Fidelity	1.73%

Reported ADAPTIVE BIOTECHNOLOGIES CORP. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ADAPTIVE BIOTECHNOLOGIES CORP. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Viking Global Entities	20.35%	DEF14A
BlackRock	9.06%	13F
ARK Investment Management LLC	8.69%	13G
Matrix Capital Management Master Fund, LP	7.85%	DEF14A
Vanguard Group	7.65%	13F
Chad Robins	2.73%	DEF14A
State Street	1.82%	13F
Goldman Sachs	1.28%	13F
Harlan Robins, PhD	1.22%	DEF14A
Julie Rubinstein	0.76%	DEF14A

Percentages above are of 147,368,324 shares outstanding, as reported by ADAPTIVE BIOTECHNOLOGIES CORP. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ADAPTIVE BIOTECHNOLOGIES CORP.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At ADAPTIVE BIOTECHNOLOGIES CORP.'s shareholder meeting held 2024-06-07, in the 2023-2024 proxy season, 205 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,006 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. No official Form 8-K vote tally has been matched to this meeting, so this page states no certified outcome for its most widely held ballot item. On that item — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — the reporting funds cast 84% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

ADAPTIVE BIOTECHNOLOGIES CORP. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.